Zepbound

How does Zepbound work?

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist — meaning it mimics two naturally occurring hormones in your body that play key roles in appetite regulation, blood sugar control, and metabolism.

Here's how it works:

• GLP-1 (glucagon-like peptide-1) activation: Slows gastric emptying (how quickly food leaves your stomach), increases feelings of fullness (satiety), reduces appetite, and helps regulate blood sugar by stimulating insulin release.
• GIP (glucose-dependent insulinotropic polypeptide) activation: Enhances the GLP-1 effects and may have additional benefits on fat metabolism, energy expenditure, and appetite regulation. The exact role of GIP in weight loss is still being studied, but the dual mechanism appears to produce greater weight loss than GLP-1 agonists alone.

Together, these two pathways produce several effects that contribute to weight loss:

• Reduced appetite and food cravings — Most patients report significantly decreased hunger and reduced interest in food, particularly high-calorie foods.
• Slower gastric emptying — Food stays in your stomach longer, helping you feel full faster and for a longer period after eating.
• Improved insulin sensitivity — Better blood sugar regulation can reduce the cycle of blood sugar spikes and crashes that drive cravings.
• Potential effects on the brain's reward system — GLP-1 receptors in the brain may reduce the reward value of food, helping break patterns of emotional or binge eating.

Zepbound is injected once weekly. Because of its long half-life (approximately 5 days), steady-state levels build over several weeks of treatment, which is why the dose is gradually increased over time.

Effects on appetite are often noticeable within the first 1–2 weeks, while meaningful weight loss typically becomes apparent after 8–12 weeks of treatment.

How hard is it to find Zepbound in stock?

Zepbound (tirzepatide) is one of the most in-demand medications in the United States right now — and while supply has improved significantly since 2024, finding it at your pharmacy can still be hit or miss depending on your dose and location. We've assigned it a findability score of 55 out of 100, meaning patients should expect moderate difficulty locating this medication.

What's Driving the Score

Zepbound experienced severe supply constraints from its launch in late 2023 through most of 2024, driven by unprecedented demand for GLP-1 weight loss medications. Tirzepatide (the active ingredient in both Zepbound and Mounjaro) was placed on the FDA Drug Shortage Database in December 2022 and remained there until October 2024, when the FDA determined that Eli Lilly could meet market demand. The FDA upheld this decision in December 2024, officially resolving the shortage.

However, "resolved" doesn't mean every pharmacy has it on the shelf. The FDA has acknowledged that patients may still experience intermittent localized supply disruptions as the medication moves through the supply chain. This is especially true for medications like Zepbound that require refrigeration and come in multiple dose strengths — pharmacies may stock some doses but not others.

A major development: In May 2025, CVS Health announced it would drop Zepbound from its preferred formulary starting July 2025, instead prioritizing coverage of Wegovy (semaglutide). This means CVS Caremark members may face higher costs or need prior authorization for Zepbound, potentially affecting demand distribution across pharmacies (Source: Pharmacy Times).

The end of the compounded tirzepatide market has also shifted demand. When the FDA removed tirzepatide from the shortage list, compounding pharmacies were required to stop producing copycat versions. An estimated up to 2 million patients were using compounded tirzepatide, many of whom are now transitioning to brand-name Zepbound — adding pressure on pharmacy supply.

What This Means for Patients

Unlike ADHD stimulants, Zepbound is not a controlled substance, so there are no DEA production quotas or pharmacy stocking limits to contend with. The main barriers to access are insurance coverage and cost. Many insurance plans still don't cover weight loss medications, and Zepbound's list price is approximately $1,000/month.

Eli Lilly has taken steps to improve affordability, including offering single-dose vials at a lower price point (~$400/month) and a commercial savings card that can reduce copays for eligible patients with insurance coverage.

If your pharmacy doesn't have your prescribed Zepbound dose in stock, Medfinder can help you find a pharmacy near you that does — saving you time and ensuring you don't miss a dose in your treatment plan.

Who Can Prescribe Zepbound?

Zepbound is a prescription medication but is not a controlled substance, which means any licensed prescriber can write a prescription for it without the DEA restrictions that apply to stimulant medications. The following providers commonly prescribe Zepbound:

• Primary Care Physicians (PCPs) — The most common prescribers. Many family medicine doctors and internists prescribe Zepbound as part of comprehensive weight management.
• Endocrinologists — Specialists in hormonal and metabolic conditions. Particularly relevant for patients with type 2 diabetes or metabolic syndrome.
• Obesity Medicine Specialists — Board-certified in obesity medicine. These specialists have deep expertise in GLP-1 medications and weight management.
• Cardiologists — May prescribe for patients where obesity is a cardiovascular risk factor.
• Pulmonologists / Sleep Medicine Specialists — May prescribe for obstructive sleep apnea (OSA), following Zepbound's December 2024 approval for this indication.
• Nurse Practitioners (NPs) and Physician Assistants (PAs) — Can prescribe in most states.

Zepbound can also be prescribed via telehealth. Several direct-to-consumer telehealth platforms now offer virtual consultations specifically for weight management medications, though patients should ensure they're receiving FDA-approved brand-name Zepbound and not compounded alternatives.

The bigger challenge with Zepbound is usually insurance coverage and cost, not getting the prescription itself. If your pharmacy doesn't stock your dose, Medfinder can help you locate one that does.

Is Zepbound a controlled substance?

No, Zepbound is not a controlled substance. Unlike ADHD stimulant medications (such as Adderall or Vyvanse), Zepbound has no DEA scheduling or restrictions related to abuse potential.

This means:

• Automatic refills are possible — Your pharmacy can set up auto-refill for Zepbound.
• No prescription quantity limits — Your provider can write prescriptions for 90-day supplies.
• No DEA production quotas — Eli Lilly can manufacture as much tirzepatide as it needs to meet demand.
• Easy prescription transfers — You can transfer your Zepbound prescription between pharmacies without needing a new script from your doctor.
• Telehealth prescribing — No special waivers needed for prescribing via telemedicine.

While Zepbound itself is not a controlled substance, it is only available by prescription. You cannot purchase it over the counter. Additionally, the FDA has cracked down on compounded and counterfeit versions of tirzepatide — patients should only use FDA-approved Zepbound obtained from licensed pharmacies.

The primary access barriers for Zepbound are insurance coverage and cost, not regulatory restrictions. Many insurance plans do not cover weight loss medications, and Zepbound's list price is approximately $1,000/month without coverage.

If your pharmacy doesn't carry Zepbound, Medfinder can help you find a pharmacy near you that has your prescribed dose in stock.

Common Side Effects of Zepbound

The most common side effects of Zepbound are gastrointestinal and tend to be most pronounced during the first few weeks and during dose increases. They typically improve as your body adjusts.

Most Common Side Effects

• Nausea — The most frequently reported side effect. Usually mild to moderate and improves over time. Eating smaller meals can help.
• Diarrhea
• Vomiting — More common during dose escalation periods.
• Constipation
• Abdominal pain / stomach discomfort
• Decreased appetite — This is part of how the medication works, but severe appetite loss should be discussed with your provider.
• Indigestion / acid reflux (GERD)
• Injection site reactions — Redness, swelling, or itching at the injection site.
• Fatigue
• Hair thinning — Reported by some patients, likely related to rapid weight loss rather than the medication itself.

Less Common but Serious Side Effects

Contact your healthcare provider or seek medical attention if you experience:

• Signs of pancreatitis (severe, persistent abdominal pain that may radiate to the back)
• Gallbladder problems (pain in the upper right abdomen, especially after meals)
• Kidney problems (changes in urination, swelling in legs/ankles)
• Severe allergic reactions (rash, swelling of face/throat, difficulty breathing)
• Changes in vision (may indicate thyroid issues)
• Hypoglycemia (low blood sugar) — especially if taking other diabetes medications

Boxed Warning: Zepbound carries a boxed warning about the risk of thyroid C-cell tumors based on animal studies. It is not known whether tirzepatide causes these tumors in humans. Zepbound should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Tip: Most GI side effects can be minimized by eating smaller meals, avoiding high-fat foods, staying hydrated, and following the gradual dose escalation schedule. Don't skip dose increases too quickly.

Final Thoughts on Zepbound

Zepbound represents a major advance in weight management — as the first and only dual GIP/GLP-1 receptor agonist, it delivers the most significant weight loss results of any FDA-approved obesity medication to date. Clinical trials showed average weight loss of over 20%, and the recent SURMOUNT-5 trial confirmed it outperforms Wegovy by a substantial margin.

The good news: Zepbound is no longer in shortage. The FDA officially resolved the tirzepatide shortage in late 2024, and Eli Lilly has invested billions in manufacturing capacity. Unlike ADHD stimulants, Zepbound is not a controlled substance, so there are no DEA quotas or pharmacy stocking restrictions.

The challenge remains cost and insurance coverage. With a list price near $1,000/month and many plans not covering weight loss medications, affordability is the biggest barrier for most patients. CVS Caremark's decision to drop Zepbound from its preferred formulary in favor of Wegovy may further complicate access for some patients. If you have insurance coverage, check Eli Lilly's savings card program. If paying cash, the single-dose vial option (~$400/month) offers a more affordable path.

Don't let pharmacy availability slow down your treatment. Medfinder helps you find pharmacies near you that currently stock your prescribed Zepbound dose — so you never have to miss a weekly injection or spend time calling around.

Search for Zepbound availability near you and stay on track with your weight management goals.